se of the Skin Cancer Quality of Life Impact Tool (SCQOLIT) – a feasibility study in nonmelanoma skin cancers

Oxford University Hospitals NHS Trust0 sites300 target enrollmentFebruary 3, 2016

Overview

2016 results presented at ISOQOL in 2016: https://www.ncbi.nlm.nih.gov/pubmed/27650289 (added 29/04/2019) 2. 2017 results presented at the 97th Annual Meeting of the British Association of Dermatologists in 2017: http://www.bad.org.uk/shared/get-file.ashx?id=5779&itemtype=document (added 29/04/2019)

Registry

who.int

Start Date

February 3, 2016

End Date

March 30, 2017

Last Updated

6 years ago

Study Type

Interventional

Sex

All

Sponsor

•1\. Aged 18 years or above
•2\. Participant is willing and able to give informed consent for participation in the study.
•3\. All patients with a histopathological diagnosis of NMSC (primary or recurrent disease)
•4\. All treatments used for NMSC will be included in the study; excision, shave excision, curettage and cautery, Mohs micrographic surgery, photodynamic therapy and topical treatments e.g. imiquimod cream

•1\. Concurrent internal malignancy as this is likely to significantly influence quality of life (QOL)
•2\. Patients referred on to other specialties for management of their skin cancer e.g. Plastic surgeons / Clinical oncology
•3\. Other significant dermatological diseases e.g. severe inflammatory or blistering skin conditions as this may influence QOL
•4\. Inability to consent for themselves